SY-3505

DRUG3 trials

Sponsors

Shouyao Holdings (Beijing) Co. LTD

Conditions

Advanced Solid TumorNon-small Cell Lung CancerNon-small-cell Lung Carcinoma

Phase 1

Phase I/II Study of SY-3505 in Patients With ALK-positive Advanced Non-small Cell Lung Cancer

Shouyao Holdings (Beijing) Co. LTDNon-small Cell Lung Cancer

Start: 2020-04-26End: 2024-08-26Target: 150Updated: 2023-02-14

A Study of SY-3505 in Patients With Advanced LTK Fusion-Positive Solid Tumors

RecruitingNCT06037317

Shouyao Holdings (Beijing) Co. LTDAdvanced Solid Tumor

Start: 2024-05-30End: 2026-05-30Target: 38Updated: 2024-02-02

Phase 2

Phase II Study of SY-3505 in Patients With ALK-positive NSCLC Who Have Failed Prior Second-Generation ALK TKI

Shouyao Holdings (Beijing) Co. LTDNon-small-cell Lung Carcinoma

Start: 2023-06-30End: 2025-06-10Target: 153Updated: 2023-08-25

Related Papers

Ficonalkib (SY-3505) in Advanced ALK-Positive NSCLC: A Multicenter, Open-Label, Single-Arm, Phase 1/2 Study.

2024-01-293 citations

Efficacy and safety of SY-3505, a third-generation ALK TKI, in <i>ALK</i>-positive advanced non-small cell lung cancer: Results from a phase I/II, multi-center study.

Journal of Clinical Oncology2023-06-011 citations